Cassava Sciences Rebrands as Filana Therapeutics, Updates Ticker

Cassava Sciences ( (SAVA) ) has provided an update.

Cassava Sciences, Inc., a Nasdaq-listed biotechnology company, announced on March 10, 2026 that it has rebranded as Filana Therapeutics, Inc. and will trade under the new ticker symbol FLNA. The new corporate identity aligns the company with its strategic focus on developing filamin A–modulating therapies for central nervous system disorders, particularly tuberous sclerosis complex (TSC)-related epilepsy.

Trading under the FLNA ticker on the Nasdaq Capital Market was scheduled to begin on March 11, 2026, marking a visible shift in the company’s market presence. By centering its brand on filamin A biology in an indication where most patients remain refractory to current treatments, Filana Therapeutics is signaling a renewed scientific and commercial focus that could sharpen its positioning in the CNS drug development landscape and draw attention from investors following high‑need epilepsy markets.

The most recent analyst rating on (SAVA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.

Spark’s Take on SAVA Stock

According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.

The score is driven down primarily by weak financial performance (no revenue, sizable losses, and continued cash burn) and bearish technical trends (below major moving averages with negative MACD). Valuation also offers limited support due to a negative P/E and no dividend.

To see Spark’s full report on SAVA stock, click here.

More about Cassava Sciences

Filana Therapeutics, Inc., formerly Cassava Sciences, Inc., is a biotechnology company listed on Nasdaq that focuses on developing novel, investigational therapies targeting the filamin A protein. Its primary aim is to treat central nervous system disorders, notably tuberous sclerosis complex (TSC)-related epilepsy, as well as other diseases linked to dysregulation or overexpression of filamin A.

The company operates in the high‑risk, research‑intensive drug discovery and development segment, with all current pharmaceutical assets still in investigational stages and not approved in any jurisdiction. Filana’s programs target an area of significant unmet medical need, as a majority of TSC-related epilepsy patients remain refractory to existing antiepileptic treatments in the U.S.

The firm cautions that its R&D programs are long, complex and costly, and that early-stage clinical or preclinical data may not predict later-stage outcomes or regulatory approval. It underscores that investing in its publicly traded securities involves substantial risk, including the possibility of a total loss of invested capital for shareholders.

Average Trading Volume: 836,532

Technical Sentiment Signal: Sell

Current Market Cap: $102.4M

See more insights into SAVA stock on TipRanks’ Stock Analysis page.